ROTH Capital Partners Acts as Lead Placement Agent for
Q BioMed Inc. (OTCQB: QBIO) in its
$5.5 Million Follow-On


For more information please contact:

Investment Banking
Eric B. Cheng
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1901

James Antonopoulos
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1906

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
Nazan Akdeniz
Senior Vice President
(949) 720-5740
Lou Ellis
Senior Vice President
(949) 720-5739

Transaction Information
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, has closed an public offering of an aggregate of 1,711,875 shares of common stock, together with warrants to purchase up to 1,711,875 shares of common stock, at a public offering price of $3.20 per share and associated warrant. Each warrant will have an exercise price of $3.20 and will expire five years from the date of issuance. The gross proceeds for Q BioMed Inc. from the offering are approximately $5.5 million.

Q BioMed Inc. anticipates that the proceeds from the offering will provide Q BioMed the required capital to execute on several significant milestones in the first half of 2018 and beyond. These catalysts include;

  • The commercialization of our licensed FDA approved drug, Strontium Chloride 89 (SR89), a non-opioid therapeutic drug for the treatment of skeletal pain associated with metastatic cancers.

  • Initiating the planning and IND filing for a Phase 4 post-marketing study to expand the indication of the approved SR89, labeling it as chemotherapeutic (a cancer therapy) for skeletal metastases, significantly improving the revenue potential for the drug.

  • The filing of an IND for a pivotal phase ll/lll clinical program to test the efficacy of QBM-001, a pro-drug for the treatment of young children with a rare autistic spectrum disorder that severely inhibits their ability to communicate.

  • Continued R&D on the novel chemotherapeutic drug for liver cancer.

  • Completion of optimization and pre-clinical testing of the first-in-class glaucoma drug Man-01 for the treatment of open angle glaucoma, a disease affecting more than 60,000,000 people around the world.

ROTH Capital Partners acted as lead placement agent for the offering.

About Q BioMed Inc.
Q BioMed, Inc. is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to ensure they meet their developmental potential, enabling them to provide products to patients in need. For more information, please visit
(Source: Company Press Release | 1/30/18)

About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit

Date of Announcement: 2/2/18

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2018.